Sugi Predict

Sugi Predict / Compounds / SCHEMBL4039055

SCHEMBL4039055

SCHEMBL4039055

CCCC(NC(=O)c1ccc(N(C)C)cc1)C(=O)N1CCC2C1C(=O)CN2S(=O)(=O)C(=O)c1cccnc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CTSK P43235 4/20 0.54
▸ CHRNB2 P17787 1/20 0.37
▸ CHRNA7 P36544 1/20 0.37
▸ CHRNA4 P43681 1/20 0.37
▸ RAB9A P51151 1/20 0.36
▸ PREP P48147 3/20 0.36
▸ FAP Q12884 2/20 0.36
▸ CCR1 P32246 2/20 0.36
▸ CTSV O60911 2/20 0.34
▸ CTSL P07711 2/20 0.34
▸ CTSS P25774 2/20 0.34
▸ ACE P12821 1/20 0.34
▸ MC4R P32245 1/20 0.34
▸ MC3R P41968 1/20 0.34
▸ MC1R Q01726 1/20 0.34
▸ GPR132 Q9UNW8 3/20 0.33
▸ ALDH1A1 P00352 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4046916 0.92 CTSK (0.65) CTSKCHRNB2CHRNA7CHRNA4RAB9A
SCHEMBL4043857 0.92 CTSK (0.44) CTSKPREPFAPCCR1CTSV
SCHEMBL4041145 0.91 CTSK (0.45) CTSKRAB9APREPFAPCCR1
SCHEMBL4040234 0.91 CTSK (0.54) CTSKRAB9APREPFAPCCR1
SCHEMBL4041463 0.90 CTSK (0.43) CTSKCHRNB2CHRNA7CHRNA4RAB9A
SCHEMBL4041112 0.90 CTSK (0.46) CTSKPREPFAPCCR1CTSV
SCHEMBL4041298 0.90 CTSK (0.54) CTSKCHRNB2CHRNA7CHRNA4RAB9A
SCHEMBL4040328 0.89 CTSK (0.42) CTSKPREPFAPCCR1CTSV
SCHEMBL4045200 0.89 CTSK (0.45) CTSKRAB9APREPFAPCCR1
SCHEMBL4040150 0.88 CTSK (0.41) CTSKPREPFAPCCR1CTSV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 — — EP claimed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 — — US claimed
EP-1546150-A1 BIOLOGICALLY ACTIVE COMPOUNDS Amura Therapeutics Limited (GB) 2005-06-29 — — EP claimed
WO-2004007501-A1 BIOLOGICALLY ACTIVE COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2004-01-22 — — WO claimed
EP-1546150-B1 PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES AMURA THERAPEUTICS LTD (GB) 2009-03-04 — — EP disclosed
US-20060100431-A1 Biologically active compounds AMURA THERAPEUTICS LIMITED (GB) 2006-05-11 — — US disclosed
EP-1546150-A1 BIOLOGICALLY ACTIVE COMPOUNDS Amura Therapeutics Limited (GB) 2005-06-29 — — EP disclosed
WO-2004007501-A1 BIOLOGICALLY ACTIVE COMPOUNDS AMURA THERAPEUTICS LIMITED (GB) 2004-01-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060100431-A1 Biologically active compounds SOST, CTSK, CTSS CTSK 2/4885CHRNB2 3423/4885CHRNA7 1466/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.